If so, you may be interested to know that a doctor in your area is conducting a clinical study to assess the safety and effectiveness of a medication in patients with plaque psoriasis. In this study, patients will switch from Enbrel® to the study medication, which is FDA-approved to treat chronic severe plaque psoriasis but has not been studied in psoriasis patients who are switching treatments.
To qualify for participation in this research study, you must:
· Be between the ages of 18 and 75 years old
· Have been diagnosed with plaque psoriasis
· Have been treated with Enbrel® (etanercept) for at least the past 4 months
· Currently have psoriatic lesions
If you qualify and choose to participate in this study, you will receive an initial consultation, study-related examinations, and study medication at no cost to you. Compensation for travel may also be provided.
To learn more, please visit our website at: